Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2015

View Archived Issues

Effects of RO-5506284 assessed by longitudinal beta-amyloid PET imaging

Takeda submits Japanese NDA for three-drug packs to eradicate H. pylori

Eklira Genuair approved in Japan for COPD

Duac combination gel approved in Japan for acne vulgaris

Merck & Co. describes novel IRAK-4 inhibitor with efficacy in inflammation

Selective sodium channel blockers identified at Merck & Co.

Boehringer Ingelheim anti-CD37 MAb gains US orphan status for CLL

Sonidegib named US orphan drug for medulloblastoma

Preliminary data presented from phase II GTx-758 study

EMA validates Zinbryta MAA for relapsing forms of MS

STADA and Hetero Labs plan to form joint venture

Roche and Genentech patent JAK inhibitors

Melinta Therapeutics patent new antimicrobials

CHMP recommends approval of empagliflozin/metformin for type 2 diabetes

MirImmune licenses RXi's self-delivering RNAi technology to develop cancer cell therapies

EMA committee hands down positive opinion for Lenvima in differentiated thyroid carcinoma

Aduro and Novartis establish immune-oncology collaboration

Merck Serono and Intrexon to develop CAR-T therapy

BioDelivery Sciences reports data from phase III study of clonidine gel for diabetic neuropathy

DRM-01 significantly improves acne in a phase IIa trial

Dutch Cancer Society awards grant to develop patient tumor organoids to personalize therapy

The development of genome-wide gain-of-function transcriptional activation screening

Trius divulges new gyrase inhibitors

Allergan patents FPR2 modulators

Sichuan Haisco Pharmaceutical patents FFAR1 agonists

rVSV-ZEBOV Ebola vaccine candidate set for Sierra Leone STRIVE trial

FDA approves new tablet formulation of iron chelator deferasirox

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...